Summary of evidence and Expert Committee recommendations
Prednisolone was included in the core list of the first EMLc for this indication in 2007. The EMLc Subcommittee considered that allergic disorders (e.g., rhinitis, conjunctivitis, urticaria and contact dermatitis) are a common problem in children and therefore medicines for their treatment could be considered essential.
In consideration of the need for corticosteroids for allergic disorders in children, the EMLc Subcommittee noted that prednisolone is licensed for 'steroid responsive conditions'. While recognizing the need for systemic steroids in severe allergic reactions, the Subcommittee noted that for conditions such as allergic rhinitis and conjunctivitis, topical steroids or topical antihistamines have been shown to be effective and safer.